Tetraphase Pharmaceuticals Inc. (TTPH)

4.62
0.04 0.87
NASDAQ : Health Technology
Prev Close 4.58
Open 4.60
Day Low/High 4.59 / 4.74
52 Wk Low/High 3.36 / 49.60
Volume 32.43K
Avg Volume 445.90K
Exchange NASDAQ
Shares Outstanding 2.72M
Market Cap 13.77M
EPS -27.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Perilous Reversal Stock: Tetraphase Pharmaceuticals (TTPH)

Perilous Reversal Stock: Tetraphase Pharmaceuticals (TTPH)

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Tetraphase Pharmaceuticals (TTPH) Reaches New Lifetime High Today

Tetraphase Pharmaceuticals (TTPH) Reaches New Lifetime High Today

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Announces Positive Top-line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Announces Positive Top-line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive...

Tetraphase Pharmaceuticals Added To NASDAQ Biotechnology Index

Tetraphase Pharmaceuticals Added To NASDAQ Biotechnology Index

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced...

Tetraphase Pharmaceuticals To Present At The Oppenheimer 25th Annual Healthcare Conference

Tetraphase Pharmaceuticals To Present At The Oppenheimer 25th Annual Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic ...

New Lifetime High Reached: Tetraphase Pharmaceuticals (TTPH)

New Lifetime High Reached: Tetraphase Pharmaceuticals (TTPH)

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Pharmaceuticals (TTPH) Is Today's Perilous Reversal Stock

Tetraphase Pharmaceuticals (TTPH) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic ...

Tetraphase Pharmaceuticals Reports Third-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals Reports Third-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operating highlights for the third quarter ended September 30, 2014.

First Week of December 20th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of December 20th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the December 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new December 20th contracts and identified one put and one call contract of particular interest.

Tetraphase Pharmaceuticals Announces Closing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Closing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the closing of its underwritten public offering of 4,542,500 shares of common stock at an offering price of $19.

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a pre-market mover with heavy volume candidate

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 3,950,000 shares of common stock for a public offering price of $19.

Tetraphase Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering.

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High Today

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High Today

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Pharmaceuticals Announces Presentation Of Data At IDWEEK On The Activity Of Eravacycline Against Multidrug-Resistant Bacteria

Tetraphase Pharmaceuticals Announces Presentation Of Data At IDWEEK On The Activity Of Eravacycline Against Multidrug-Resistant Bacteria

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage...

Tetraphase Pharmaceuticals Announces Initiation Of Pivotal Portion Of IGNITE 2 Phase 3 Trial Of Eravacycline In CUTI

Tetraphase Pharmaceuticals Announces Initiation Of Pivotal Portion Of IGNITE 2 Phase 3 Trial Of Eravacycline In CUTI

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced initiation of patient enrollment in the pivotal portion of its IGNITE 2 Phase 3 clinical trial, a two-part trial studying the efficacy and safety of ...

Tetraphase Pharmaceuticals (TTPH) Strong On High Relative Volume Today

Tetraphase Pharmaceuticals (TTPH) Strong On High Relative Volume Today

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a strong on high relative volume candidate

New Lifetime High For Tetraphase Pharmaceuticals (TTPH)

New Lifetime High For Tetraphase Pharmaceuticals (TTPH)

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Today Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Today Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Pharmaceuticals To Present At BioCentury’s 2014 NewsMakers In The Biotech Industry Conference

Tetraphase Pharmaceuticals To Present At BioCentury’s 2014 NewsMakers In The Biotech Industry Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic ...

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Tetraphase Oral Antibiotic Data Look Good

Tetraphase Oral Antibiotic Data Look Good

Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.

Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data From Lead-in Of IGNITE 2 Phase 3 Trial Of Eravacycline In CUTI Support Advancement To Pivotal Portion

Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data From Lead-in Of IGNITE 2 Phase 3 Trial Of Eravacycline In CUTI Support Advancement To Pivotal Portion

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and ...

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Previewing Tetraphase Oral Antibiotic Study Results

Previewing Tetraphase Oral Antibiotic Study Results

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

Tetraphase To Present Research At ICAAC On Its Novel Chemistry Platform’s Ability To Address Antibiotic Resistance

Tetraphase To Present Research At ICAAC On Its Novel Chemistry Platform’s Ability To Address Antibiotic Resistance

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead...

TheStreet Quant Rating: D- (Sell)